Hepatitis C Virus – Epidemiology – Mature Markets Data

Clarivate Epidemiology’s coverage of  hepatitis c virus (HCV) comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the incidence and prevalence of HCV for each country, as well as annualized case counts projected to the national population.

Clarivate Epidemiology’s HCV forecast will answer the following questions:

  • How will changes in the levels of exposure to known risk or protective factors affect the number of people diagnosed with HCV per year?
  • How will improvements in survival change the number of people living with HCV?
  • Of all people with HCV, how many in each country across the world have been formally diagnosed?
  • Of all people diagnosed with HCV, how many in each country across the world are drug-treated?
  • How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of HCV over the forecast period?

All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.

In total, Clarivate Epidemiology forecasts 49 HCV patient populations, as follows:

  • Diagnosed GT3 viremic non-cirrhotic prevalent cases
  • Viremic cirrhotic prevalent cases
  • Drug-treatment GT3 viremic non-cirrhotic svr events
  • Drug-treatment GT2 viremic cirrhotic events
  • Viremic non-cirrhotic prevalent cases
  • Diagnosed GT2 viremic cirrhotic prevalent cases
  • GT3 viremic prevalent cases
  • Drug-treatment GT4+ viremic non-cirrhotic events
  • Drug-treatment GT3 viremic cirrhotic svr events
  • Drug-treatment GT1 viremic non-cirrhotic events
  • … and many more (details available on request).

Note: coverage may vary by country.

launch Related Market Assessment Reports